This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including. Fosphenytoin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Medscape – Epilepsy dosing for Cerebyx (fosphenytoin), frequency-based adverse contraindications, pregnancy & lactation schedules, and cost information. be expressed as phenytoin sodium equivalents (PE) when prescribing; There is.

Author: Gomuro Shakus
Country: Kazakhstan
Language: English (Spanish)
Genre: Travel
Published (Last): 16 March 2018
Pages: 413
PDF File Size: 7.16 Mb
ePub File Size: 2.18 Mb
ISBN: 121-4-20797-466-1
Downloads: 68942
Price: Free* [*Free Regsitration Required]
Uploader: Dabar

John’s wort may vary widely based on preparation. Each 2 mL vial contains mg PE. Genetic toxicity studies showed that fosphenytoin was not mutagenic in bacteria or in mammalian cells in vitro. Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin.

Levetiracetam The metabolism of Fosphenytoin can be decreased when combined with Levetiracetam. These have prrscribing thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression see section 4.

Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin. Aminophenazone The metabolism of Fosphenytoin can be decreased when combined with Aminophenazone. Last updated on eMC: Bentonite Bentonite can cause a decrease informmation the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.

  INTRODUCTORY FUNCTIONAL ANALYSIS WITH APPLICATIONS BY ERWIN KREYSZIG PDF

Cerivastatin The metabolism of Fosphenytoin can be increased when combined with Cerivastatin. The background risk of major birth defects and miscarriage for the indicated population is unknown. Cinolazepam The serum concentration of Fosphenytoin can be increased when it is combined with Cinolazepam.

Other signs include tremor, hyperreflexia, lethargy, slurred speech, nausea, vomiting, coma and hypotension.

Fosphenytoin sodium injection is a prodrug intended for parenteral administration; its active metabolite is phenytoin. Table 9 displays dosing information for seizure treatment or prophylaxis maintenance dose in children. Note that Pro-Epanutin has important differences in administration from parenteral phenytoin sodium. Dextofisopam The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dextofisopam. Phenytoin is metabolized by hepatic cytochrome P enzymes CYP2C9 and CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.

Drugs that may increase phenytoin serum levels. Clotrimazole The metabolism of Fosphenytoin can be increased when combined with Clotrimazole. Golimumab The metabolism of Fosphenytoin can be increased when combined with Golimumab. Musculoskeletal and connective tissue disorders.

Fosphenytoin – DrugBank

Metyrosine Fosphenytoin may increase the sedative activities of Metyrosine. Bufotenine The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Bufotenine. Phenytoin can substantially reduce the concentrations of delavirdine.

  ALBIZIA VERSICOLOR PDF

Musculoskeletal and connective tissue disorders Uncommon muscular weakness, muscle twitching, muscle spasms Not known systemic lupus erythematosus, polyarthritis, Purple Glove Syndrome see section 4.

Chlormadinone The metabolism of Fosphenytoin can be decreased when combined with Chlormadinone. Barbital The metabolism of Fosphenytoin can be increased when combined with Barbital. Loperamide The metabolism of Fosphenytoin can be decreased when combined with Loperamide.

In addition, advise the patient that these signs and symptoms should be reported even if mild or when occurring after extended use [see Warnings and Precautions 5.

Fosphenytoin

Cyclandelate The metabolism of Fosphenytoin can be decreased when combined with Cyclandelate. Docetaxel The metabolism of Fosphenytoin can be decreased when combined with Docetaxel. Ivermectin The metabolism of Fosphenytoin can be decreased when combined with Ivermectin. Phenytoin may also raise the serum glucose concentrations in diabetic patients.

A small percentage of individuals who have been treated with phenytoin the active metabolite of CEREBYX have been shown to metabolize the drug slowly. Ixazomib The metabolism of Fosphenytoin can be decreased when combined with Ixazomib. Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin.